Columbia Laboratories, Inc. CBRX has entered into an asset purchase agreement with Actient Pharmaceuticals LLC, a privately-held specialty therapeutics company, for STRIANT^® in the United States.
Under this agreement, Columbia has sold STRIANT to Actient for a combination of cash upfront and royalties on annual sales of STRIANT above a certain threshold. The Company also licensed to Actient certain intellectual property related to the underlying progressive technology for use in the treatment of hypogonadism and other indications related to low testosterone levels in men.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in